Exact Sciences 

M$872
254
+M$0+0% Wednesday 18:52

統計

當日最高
872
當日最低
872
52週最高
1,660
52週最低
760.88
成交量
1,400
平均成交量
73
市值
-
市盈率
-
股息收益率
-
股息
-

即將到來

收益

30Oct預期
Q4 2022
Q1 2023
Q2 2023
Q4 2023
Q1 2024
Q2 2024
下一個
-13.27
-9.41
-5.54
-1.68
預期每股收益
-3.8526196581
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 EXAS.MX 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Show more...
首席執行官
Mr. Kevin T. Conroy
員工
6300
國家
United States
ISIN
US30063P1057

上市公司